Needham & Company
-
Needham & Company Reiterates Intra-Cellular Therapies (ITCI) at Buy with $65 PT, Sees Caplyta's Growth Accelerating & Potentially Beating Expectations
-
Needham & Company Reiterates Intra-Cellular Therapies (ITCI) at Buy, Anticipates Uptick Following Earnings
-
Intra-Cellular Therapies (ITCI) PT Raised to $65 at Needham & Company
-
Intra-Cellular Therapies Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Intra-Cellular Therapies (ITCI) Prices 9.52M Share Offering at $42/sh
-
Intra-Cellular Therapies Prices Public Offering of Common Stock
-
Intra-Cellular Therapies (ITCI) PT Raised to $59 at Needham & Company; Sees >$800M in Caplyta Sales by 2026
-
Needham & Company Previews Intra-Cellular Therapies (ITCI) Dec. 17th PDUFA for Caplyta
-
Needham & Company Starts Intra-Cellular Therapies (ITCI) at Buy
-
Intra-Cellular Therapies to Present at the 15th Annual Needham Healthcare Conference